How Core Laboratories Inc. (CLB) Affects Rotational Strategy Timing
This article analyzes Core Laboratories Inc. (CLB) and its impact on rotational strategy timing, identifying positive near-term sentiment but a weak mid-term bias within a long-term strength context. It provides institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for CLB. The analysis suggests elevated downside risk due to the absence of additional long-term support signals.
Implied Volatility Surging for Core Laboratories Stock Options
Implied volatility for Core Laboratories Inc. (CLB) stock options is notably high, particularly for the June 18, 2026 $25.00 Call, suggesting that the market anticipates a significant price movement. Despite this, analysts have a negative outlook on the company, with Core Laboratories holding a Zacks Rank #4 (Sell) and recent downward revisions to earnings estimates. This situation may present an opportunity for experienced options traders to sell premium, betting on the stock not moving as much as the implied volatility suggests.
CLB News | CORE LABORATORIES INC (NYSE:CLB)
This page provides the latest news and analysis for Core Laboratories Inc. (NYSE:CLB), including its current stock price and highlights a recent press release from Zacks regarding surging implied volatility for CLB stock options.
Disciplined Growth Investors holds 4.94M CLB shares (NYSE: CLB)
Disciplined Growth Investors, Inc. has disclosed beneficial ownership of 4,937,115 common shares of Core Laboratories Inc. (NYSE: CLB), representing 10.7% of the company's class. This information comes from an amended passive investment disclosure (SCHEDULE 13G/A) filed with the SEC. The filing indicates the investor holds sole voting power over 4,653,638 shares and sole dispositive power over all 4,937,115 shares.
Core Laboratories Shareholders Back Directors, Auditor and Pay
Core Laboratories shareholders re-elected Class I directors Harvey Klingensmith and Curtis Anastasio, ratified KPMG LLP as the independent auditor for fiscal year 2026, and supported the company's executive compensation philosophy at their annual meeting. Despite this backing, TipRanks' AI Analyst "Spark" rates CLB as Neutral due to weak technicals and recent revenue decline, though partially offset by improved leverage and solid margins. The company, an oilfield services provider, helps optimize reservoir performance for the energy industry.
Core Laboratories Inc. Common Stock (NY: CLB)
This article provides an overview of recent news and financial updates related to Core Laboratories Inc. (NYSE: CLB). It includes various news headlines, earnings reports, analyst insights, and stock performance updates for the company, spanning from late 2025 to May 2026. The content highlights the impact of geopolitical events and operational challenges on Core Laboratories' stock and earnings.
Core Laboratories Inc. Common Stock (NY: CLB)
This article provides recent news and market data for Core Laboratories Inc. (CLB), including its current stock price and a list of news headlines related to analyst ratings, earnings call transcripts, and its performance in response to oil market changes. The news covers events between October 2021 and May 2023, highlighting various earnings reports, analyst upgrades/downgrades, and reactions to broader economic and oil industry news.
Core Laboratories shareholders approve director elections and executive compensation
Core Laboratories Inc. shareholders approved all proposals at their recent Annual Meeting, including the re-election of two Class I directors, Harvey Klingensmith and Curtis Anastasio, and the ratification of KPMG LLP as their independent registered public accounting firm. Shareholders also provided advisory approval for the compensation of the company’s named executive officers. These approvals come despite Core Laboratories reporting first-quarter 2026 financial results that missed market expectations.
Core Laboratories Shareholders Back Directors, Auditor and Pay
Core Laboratories Inc. held its Annual Meeting of Shareholders on May 12, 2026, where investors re-elected two Class I directors, Harvey Klingensmith and Curtis Anastasio, to terms running until 2029. Shareholders also ratified KPMG LLP as the independent registered public accountant for 2026 and supported the company's executive compensation philosophy. This indicates broad support for Core Laboratories' governance and leadership structure, despite an AI analyst's "Neutral" rating on the stock due to weak technicals but partially offset by improved leverage and solid margins.
Core Laboratories (NYSE: CLB) investors back directors, auditor and pay
Core Laboratories Inc. shareholders approved all three proposals at their Annual Meeting on May 12, 2026. This included the re-election of Class I directors Harvey Klingensmith and Curtis Anastasio, the ratification of KPMG LLP as the independent registered public accountant for 2026, and an advisory vote approving the company's executive compensation program. The meeting saw strong support for these proposals, signifying shareholder confidence in the company's governance and compensation practices.
Number of shareholders of Core Laboratories Inc. – BMV:CLB
The article, titled "Number of shareholders of Core Laboratories Inc. – BMV:CLB," is an incomplete data report from TradingView. It appears to be a stub for financial information regarding Core Laboratories Inc. on the Mexican Stock Exchange, listing headings for "Period," "Value," "Change," and "Change %" but providing no actual data.
Core Laboratories (NYSE:CLB) Downgraded by Wall Street Zen to Sell
Core Laboratories (NYSE:CLB) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, while Weiss Ratings also lowered its view on the stock. Shares of CLB fell 2.3% to $13.15, trading below its 50-day and 200-day moving averages. Despite meeting Q1 earnings estimates with $0.06 EPS, the company's revenue slightly missed expectations and was down 1.4% year-over-year.
Core Laboratories (NYSE: CLB) SVP exercises restricted shares, covers taxes
Core Laboratories SVP Mark Damian Tattoli exercised 250 restricted shares on May 1, 2026. To cover tax obligations, 97 shares were disposed of, leaving him with 27,513.621 directly held shares. The filing also details his indirect holdings and states that multiple restricted share grants vest annually over six years, contingent on continued service.
Core Lab projects Q2 2026 revenue of $123M-$131M and EPS of $0.06-$0.12 amid Middle East disruptions
Core Lab (CLB) has released its projections for the second quarter of 2026, anticipating revenues between $123 million and $131 million and diluted EPS ranging from $0.06 to $0.12. These forecasts come amidst ongoing disruptions in the Middle East, which are impacting the company's financial outlook.
Core Lab projects Q2 2026 revenue of $123M-$131M and EPS of $0.06-$0.12 amid Middle East disruptions
Core Lab (NYSE: CLB) has released its projections for the second quarter of 2026, anticipating revenues between $123 million and $131 million and diluted earnings per share (EPS) ranging from $0.06 to $0.12. These projections are notably lower than current consensus estimates for both revenue and EPS. The company attributes this outlook to ongoing geopolitical disruptions in the Middle East, which are impacting its operational activities and financial performance.
Core Laboratories Earnings Call: Tech Strengths Amid Turmoil
Core Laboratories (CLB) reported a challenging Q1 due to geopolitical issues, weather, and cost inflation, resulting in a 12% sequential revenue drop and significant profitability decline. However, the company highlighted technology successes like GTX and FLOWPROFILER, and its digital data strategy, which positions it for future AI integration. Despite short-term turbulence, Core Lab maintained its shareholder return program, including buybacks and dividends, optimistic about long-term oil demand and its niche oilfield technologies.
Press Release: CORE LAB REPORTS FIRST QUARTER 2026 RESULTS
Core Laboratories (NYSE: CLB) announced its first quarter 2026 financial results, reporting revenue of $169.5 million and diluted EPS of $0.35. The company's operating income for the quarter was $22.4 million, with an operating margin of 13%. Core Lab's Free Cash Flow was $19.4 million, and it maintained its quarterly dividend of $0.10 per share.
Core Laboratories (NYSE:CLB) Shares Down 6.7% - Time to Sell?
Core Laboratories (NYSE:CLB) shares dropped 6.7% on Friday following a decline in trading volume and the stock trading below its 50-day and 200-day moving averages. Analysts maintain a consensus "Hold" rating with an average target price suggesting potential downside. The company met Q1 EPS estimates but saw revenue decline, and has set Q2 guidance.
Core Lab projects Q2 2026 revenue of $123M-$131M and EPS of $0.06-$0.12 amid Middle East disruptions
Core Lab (NYSE: CLB) has issued its financial projections for the second quarter of 2026, anticipating revenue between $123 million and $131 million and diluted EPS ranging from $0.06 to $0.12. This outlook reflects the ongoing disruptions in the Middle East, which are impacting the company's operations and financial performance. Investors will be closely watching how these geopolitical factors influence Core Lab's actual results.
Core Laboratories : 2025 Core Laboratories Annual Report
Core Laboratories has published its 2025 Annual Report, themed "Celebrating 90 Years of Innovation," highlighting its legacy of technological advancements and impact in the energy sector. The report details the company's financial strategies, including maximizing free cash flow and return on invested capital, and its commitment to returning excess capital to shareholders. Despite geopolitical uncertainties and decreased U.S. onshore activity, Core Lab achieved modest year-over-year revenue growth and strengthened its balance sheet by reducing long-term debt.
Core Laboratories Inc. (NYSE:CLB) to Issue Quarterly Dividend of $0.01
Core Laboratories Inc. (NYSE:CLB) declared a quarterly dividend of $0.01 per share, payable on June 1st to shareholders of record on May 11th. This translates to an annual payout of $0.04 and a yield of approximately 0.3%. The company's dividend payout ratio of 4.7% indicates that the dividend is well-covered by earnings, with analysts expecting future earnings to sufficiently cover the annual dividend.
Core Laboratories: Q1 Earnings Snapshot
Core Laboratories Inc. reported a Q1 loss of $789,000, or 2 cents per share, adjusted for non-recurring costs, earnings were 6 cents per share. The energy services company generated revenue of $121.8 million in the first quarter. This financial snapshot was provided by Automated Insights, utilizing data from Zacks Investment Research.
Earnings Flash (CLB) Core Laboratories Inc. Reports Q1 Revenue $121.8M, vs. FactSet Est of $123.0M
Core Laboratories Inc. (CLB) reported its Q1 revenue at $121.8 million, falling short of the FactSet estimate of $123.0 million. The company also posted adjusted EPS of $0.06 per share, which was below FactSet's estimate of $0.09. These results follow a recent cut in Q1 guidance due to the Middle East conflict.
Core Laboratories (NYSE: CLB) posts Q1 loss, guides Q2 EPS to $0.06–$0.12
Core Laboratories (NYSE: CLB) reported a first-quarter 2026 GAAP net loss of $0.02 per diluted share on revenue of $121.8 million, a decline attributed to geopolitical instability in the Middle East and severe weather. The company's non-GAAP EPS was $0.06. For the second quarter of 2026, Core Laboratories projects revenue between $123 million and $131 million and diluted EPS ranging from $0.06 to $0.12.
CORE LAB REPORTS FIRST QUARTER 2026 RESULTS
Core Laboratories Inc. reported first-quarter 2026 revenues of $121.8 million, down 12% sequentially, with a GAAP loss per share of $0.02, mainly due to geopolitical instability in the Middle East and severe weather. The company repurchased 51,781 shares and announced a Q2 2026 quarterly dividend of $0.01 per share. Despite near-term challenges, Core Lab maintains a constructive multi-year outlook, focusing on long-term shareholder value and new technology commercialization.
Core Laboratories: Q1 Earnings Snapshot
Core Laboratories Inc. (CLB) reported a Q1 loss of $789,000, or 2 cents per share, adjusted to 6 cents per share. The energy services company posted revenue of $121.8 million for the period. This financial snapshot was generated using data from Zacks Investment Research.
Core Laboratories (CLB) Projected to Post Earnings on Wednesday
Core Laboratories (CLB) is projected to announce its Q1 2026 earnings after market close on Wednesday, April 29th, with analysts expecting $0.1082 EPS and $125.354 million in revenue. The company previously beat estimates in Q4, reporting $0.21 EPS and $138.26 million in revenue, and analysts forecast approximately $1.00 EPS for both the current and next fiscal year. CLB stock is currently trading in the mid-teens, with a market cap of around $766 million, a P/E near 24.8, and a consensus "Hold" rating from Wall Street with a $12.50 target price.
How many employees work at Core Laboratories?
Core Laboratories Inc. has 3,370 employees as of December 2025, according to Revelio Labs data, marking a -0.1% year-over-year growth rate. The company, a leading provider of reservoir description and production enhancement services, has seen a slight decline in headcount since 2023. Revelio Labs also provides insights into Core Laboratories' average salary, tenure, and active job postings, which have also decreased over the past few years.
Core Laboratories Inc stock (NL0015000CZ2): Why Google Discover changes matter more now
Google's 2026 Discover Core Update significantly changes how investors receive news on companies like Core Laboratories Inc., prioritizing personalized, mobile-first content delivery. This update leverages user activity to proactively provide relevant financial insights on oilfield services, making timely information on reservoir analysis and production optimization readily available. For investors, this means faster access to market-moving news and an enhanced ability to track strategic developments in the energy sector without traditional searching.
Core Laboratories (CLB) Price Target Increased by 11.51% to 15.64
This article reports that Core Laboratories (CLB) received an increased price target of $15.64, marking an 11.51% rise. This adjustment suggests a positive re-evaluation of the company's stock outlook by analysts.
Core Laboratories (CLB) Price Target Increased by 11.51% to 15.64
Core Laboratories (CLB) recently had its price target increased by 11.51% to $15.64. This adjustment reflects a positive outlook on the company's valuation.
What's in Store for Core Laboratories Stock in Q4 Earnings?
Core Laboratories Inc. (CLB) is scheduled to release its fourth-quarter 2025 earnings on Feb. 4, with analysts expecting a profit of 20 cents per share on $132 million in revenues. While revenue is projected to increase year-over-year, the bottom line may be impacted by rising operating expenses. The Zacks financial model does not conclusively predict an earnings beat for CLB this quarter.
Core Laboratories Inc stock (NL0015000CZ2): Why Google Discover changes matter more now for oilfield
The article discusses how Google Discover's personalized content feed is increasingly influencing awareness and trading dynamics for oil services stocks like Core Laboratories Inc (NL0015000CZ2). It highlights that Discover's algorithm, by surfacing fresh, visual content on energy services, can accelerate sentiment around technological innovations and market catalysts in the oilfield sector. This shift benefits retail investors by democratizing access to niche insights, but also amplifies risks as negative news can spread rapidly.
Core Laboratories Inc stock (NL0015000CZ2): Why Google Discover changes matter more now for oilfield tech discovery?
The article discusses how Google Discover is changing the way investors perceive and track oil services stocks like Core Laboratories Inc (NL0015000CZ2). It explains that Discover’s personalized, visual content delivery can amplify retail awareness and trading dynamics for niche oilfield tech. The platform’s emphasis on fresh, visual content and specific interest matching could provide both advantages and risks for Core Laboratories Inc stock by rapidly spreading sentiment.
Core Laboratories (NYSE:CLB) Shares Cross Above 200-Day Moving Average - Here's What Happened
Core Laboratories (NYSE:CLB) saw its stock price cross above its 200-day moving average, reaching $16.95 before settling at $16.9290. The company reported a slight EPS beat for the last quarter and announced a quarterly dividend. Analysts currently rate the stock as "Hold" with a consensus price target of $12.50.
Press Releases about Core Laboratories Inc. Common Stock (NYSE:CLB)
This page aggregates press releases related to Core Laboratories Inc. (NYSE: CLB). It includes a stock quote for CLB and highlights news such as Gateway Group's upcoming conference and an article from MarketBeat discussing Halliburton as a potential investment.
Core Laboratories (NYSE: CLB) director receives 7,895 RSUs, 8,069 shares vest
Core Laboratories (NYSE: CLB) director Robert F. Martinovich reported equity-based compensation where he received a grant of 7,895 Restricted Shares (RSUs) that will vest on April 1, 2027. Additionally, 8,069 previously granted Restricted Shares vested on April 1, 2026, and were converted into common stock, which he now holds directly. The transaction was solely related to awards and the conversion of restricted equity, with no open-market purchases or sales.
Director at Core Laboratories (NYSE: CLB) gains new share awards
Core Laboratories director Curt Anastasio reported recent equity compensation activity, including the grant of 7,895 Restricted Shares which will vest after one year on April 1, 2027. He also exercised 8,069 Restricted Shares that vested on April 1, 2026, converting them into common stock, bringing his direct holdings to 23,805 shares. The transactions noted were solely acquisitions and exercises, with no open-market buying or selling.
Core Laboratories (CLB) director gains restricted stock and 8,069 shares vest
Core Laboratories (CLB) director Katherine Murray received a grant of 7,895 Restricted Shares, which will vest on April 1, 2027. Additionally, 8,069 previously granted Restricted Shares vested and converted into Common Stock, increasing her direct holdings to 29,290 shares. No shares were sold in these transactions.
Core Laboratories (NYSE: CLB) director gets 7,895 restricted shares
Core Laboratories director Temeng Kwaku was granted 7,895 restricted shares that will vest on April 1, 2027. Additionally, 8,069 previously granted restricted shares vested on April 1, 2026, and were converted into common stock, bringing Kwaku's direct holdings to 33,597 shares. These transactions were reported in a Form 4 filing.
Core Laboratories (CLB) director receives 7,895 restricted shares and holds 54,397
Core Laboratories director Martha Z. Carnes was granted 7,895 restricted shares on April 1, 2026, which will vest after one year. On the same date, 8,069 previously granted restricted shares vested and converted into common stock. Following these transactions, Ms. Carnes directly holds 54,397 shares of Core Laboratories common stock.
Core Laboratories (NYSE: CLB) director gets 7,895-share stock grant
Core Laboratories (NYSE: CLB) director Harvey Robert Klingensmith received a grant of 7,895 Restricted Shares on April 1, 2026, which will vest in one year. On the same date, 8,069 previously granted Restricted Shares vested and were converted into common stock. Following these transactions, Klingensmith directly holds 50,031 shares of Core Laboratories common stock.
CLB PE Ratio & Valuation, Is CLB Overvalued
Core Laboratories Inc (CLB) is currently in the "Fair zone" with a forward P/E ratio of 19.76, which is lower than its five-year average of 25.04. Its fair price is estimated to be between $16.10 and $28.19 based on relative valuation. The article also details CLB's P/B ratio, FCF yield, and compares its P/S ratio to competitors.
Core Laboratories (NYSE:CLB) Stock Price Passes Above 200-Day Moving Average - Here's Why
Core Laboratories (NYSE:CLB) stock recently traded above its 200-day moving average, reaching $16.70. The company beat Q4 earnings estimates with $0.21 EPS and $138.3M in revenue, and issued Q1 2026 EPS guidance of $0.110–0.150. While analysts have a "Hold" rating with a $12.50 target, institutional investors, including Ariel and Goldman Sachs, significantly increased their stakes, now owning nearly 97.8% of outstanding shares.
Core Laboratories Hits Day High with Strong 7.25% Intraday Surge
Core Laboratories, Inc. experienced a 7.25% intraday surge, reaching a high of USD 17.63, and has outperformed the S&P 500 over the past week and year. Despite this recent positive performance, the oil industry company faces challenges with longer-term stock declines and a significant drop in profits over the last year. The company maintains strong institutional ownership and currently has a P/E ratio of 28.00 and a dividend yield of 38.11%.
Precision Trading with Core Laboratories Inc. (CLB) Risk Zones
This article analyzes Core Laboratories Inc. (CLB) using AI-generated signals for precision trading, identifying strong sentiment and specific risk zones. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with defined entry, target, and stop-loss levels. The analysis provides multi-timeframe insights, highlighting resistance and support levels to optimize trading decisions.
Vanguard (NYSE: CLB) amendment shows 0 beneficial shares after realignment
The Vanguard Group filed an amendment to its Schedule 13G/A report, indicating 0 beneficial shares of Core Laboratories Inc. common stock. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries began reporting beneficial ownership separately. The filing clarifies that Vanguard itself no longer directly owns or is deemed to own shares in CLB under this realignment.
Middle East Tensions Impact Core Laboratories' First Quarter Forecast
Core Laboratories Inc. has revised its Q1 2026 financial guidance downwards due to escalating geopolitical instability in the Middle East, which has caused operational hurdles, project delays, and supply chain issues. The company now expects lower revenues, operating income, and earnings per share. Despite the negative short-term outlook, Core Laboratories, an oilfield services provider with global operations, continues to monitor the situation, recognizing the high degree of uncertainty impacting energy service providers in volatile regions.
Middle East Tensions Impact Core Laboratories' First Quarter Forecast
Core Laboratories Inc. (CLB) has lowered its financial outlook for the first quarter of 2026 due to growing geopolitical instability in the Middle East, leading to operational hurdles and project delays. The company now projects lower revenues, operating income, and earnings per share. While the short-term forecast is impacted, Core Laboratories maintains a positive long-term outlook despite the challenges for its Reservoir Description and Production Enhancement segments.
Core Laboratories Inc stock faces pressure amid oilfield services slowdown and Q4 earnings anticipat
Core Laboratories Inc (NL0015000CZ2) is experiencing stock pressure due to a slowdown in the oilfield services sector, marked by declining US rig counts and crude price volatility. Investors are anticipating its Q4 2025 earnings, with focus on margin resilience and international backlog strength, particularly given the company's strong position in reservoir analysis and production enhancement. Despite challenges, the company's low debt and attractive dividend yield offer some stability.
